1. J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 
2018 Mar 27.

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance 
Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated 
NSCLC.

Minari R(1), Bordi P(1), La Monica S(2), Squadrilli A(1), Leonetti A(1), 
Bottarelli L(3), Azzoni C(3), Lagrasta CAM(3), Gnetti L(3), Campanini N(3), 
Petronini PG(2), Alfieri R(4), Tiseo M(1).

Author information:
(1)Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
(2)Department of Medicine and Surgery, University of Parma, Parma, Italy.
(3)Pathology Unit, Department of Medicine and Surgery, University Hospital of 
Parma, Parma, Italy.
(4)Department of Medicine and Surgery, University of Parma, Parma, Italy. 
Electronic address: roberta.alfieri@unipr.it.

DOI: 10.1016/j.jtho.2018.03.013
PMID: 29596911 [Indexed for MEDLINE]